نتایج جستجو برای: 90y ibritumomab tiuxetan

تعداد نتایج: 879  

2010
Michael F. Leahy Harvey Turner

Radioimmunotherapy of indolent nonHodgkin lymphoma (NHL) has achieved objective response rates in clinical trials comparable with standard rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy, but is relatively underused in routine practice. In this article, we report our clinical experience in 142 consecutive patients who received iodine-131 rituximab radioimm...

2012
Jae-Cheol Jo Dok Hyun Yoon Shin Kim Jung Sun Park Chan-Sik Park Jooryung Huh Sang-Wook Lee Jin-Sook Ryu Cheolwon Suh

BACKGROUND Radioimmunotherapy agents have a highly significant role in autologous stem cell transplantation as they improve tolerability and increase the efficacy of the conditioning regimen. METHODS We retrospectively analyzed the efficacy and toxicity of yttrium-90 ibritumomab tiuxetan (Zevalin) combined with intravenous busulfan, cyclophosphamide, and etoposide (Z-BuCyE) compared with thos...

Journal: :Blood 2009
Robert M Sharkey Oliver W Press David M Goldenberg

Antibody-based therapies, both unconjugated antibodies and radioimmunotherapy, have had a significant impact on the treatment of non-Hodgkin lymphoma. Single-agent rituximab is an effective therapy, but it is being increasingly used with combination chemotherapy to improve the objective response and its duration. The approved anti-CD20 radioimmunoconjugates ((90)Y-ibritumomab tiuxetan or (131)I...

Journal: :Oncology 2003
Malik Juweid Gerald L DeNardo Michael Graham Julie Vose

The field of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma (NHL) has advanced significantly over the past decade, and several radioimmunoconjugates are being tested in clinical trials. Two of these antibodies target CD20: yttrium-90 (Y-90)-labeled ibritumomab tiuxetan (Zevalin) and tositumomab/iodine-131 (I-131)-labeled tositumomab (Bexxar). Other agents target either CD22 (Y-9...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2008
P L Zinzani M Tani S Fanti V Stefoni G Musuraca P Castellucci E Marchi M Farsad M Fina C Pellegrini L Alinari E Derenzini A de Vivo F Bacci S Pileri M Baccarani

BACKGROUND A prospective, single-arm, open-label, nonrandomized phase II combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus radioimmunotherapy trial was conducted to evaluate the efficacy and safety in untreated elderly diffuse large B-cell lymphoma (DLBCL) patients. PATIENTS AND METHODS From February 2005 to April 2006, in our institute we tr...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید